RxDoctor Payments Data

James Johnston, DO

Ophthalmology · Tallmadge, OHNPI 1316940174

Payments from drug & device makers

$14,368in general payments, 2019–2025

Across 353 payments — averaging $40.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
  • Alcon$3K
  • Bausch & Lomb Americas Inc.$1K
  • Oyster Point Pharma, Inc.$821
  • AbbVie$803
  • NEW World Medical,inc.$674
  • plus $5K from 40 others

What the payments were for

  • Speaking & faculty fees$2,50017%
  • Food & beverage$11,86883%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,368 in reported general payments places this provider in the 85th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$120,106
Medicare patients
379
Services billed
1,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine74$94,739
LumiganBimatoprost74$40,882
MieboPerfluorohexyloctane/Pf33$34,043
Cyclosporine33$28,913
XiidraLifitegrast18$27,789
RocklatanNetarsudil Mesylat/Latanoprost42$26,190
VyzultaLatanoprostene Bunod37$25,042
CequaCyclosporine26$23,544
Brimonidine Tartrate240$19,990
RhopressaNetarsudil Mesylate20$15,778
Pyridostigmine Bromide ErPyridostigmine Bromide15$14,096
Latanoprost622$8,042
SimbrinzaBrinzolamide/Brimonidine Tart24$7,768
Alphagan PBrimonidine Tartrate23$6,333
Travoprost31$5,976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$803$141,954171 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$1,431$86,87588 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$222$41,96862 claims
Sun Pharmaceutical Industries Inc.Cequa$408$23,54426 claims
AlconSimbrinza$2,604$7,76824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Tallmadge

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →